Cargando…
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658–62)
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Diabetes Association
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353571/ https://www.ncbi.nlm.nih.gov/pubmed/35929175 http://dx.doi.org/10.4093/dmj.2022.0131 |
| _version_ | 1784762893718257664 |
|---|---|
| author | Kawada, Tomoyuki |
| author_facet | Kawada, Tomoyuki |
| author_sort | Kawada, Tomoyuki |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9353571 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Korean Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93535712022-08-11 Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658–62) Kawada, Tomoyuki Diabetes Metab J Letter Korean Diabetes Association 2022-07 2022-07-27 /pmc/articles/PMC9353571/ /pubmed/35929175 http://dx.doi.org/10.4093/dmj.2022.0131 Text en Copyright © 2022 Korean Diabetes Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter Kawada, Tomoyuki Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658–62) |
| title | Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658–62) |
| title_full | Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658–62) |
| title_fullStr | Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658–62) |
| title_full_unstemmed | Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658–62) |
| title_short | Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658–62) |
| title_sort | clinical efficacy of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist combination therapy in type 2 diabetes mellitus: real-world study (diabetes metab j 2022;46: 658–62) |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353571/ https://www.ncbi.nlm.nih.gov/pubmed/35929175 http://dx.doi.org/10.4093/dmj.2022.0131 |
| work_keys_str_mv | AT kawadatomoyuki clinicalefficacyofsodiumglucosecotransporter2inhibitorandglucagonlikepeptide1receptoragonistcombinationtherapyintype2diabetesmellitusrealworldstudydiabetesmetabj20224665862 |